AI Article Synopsis

  • Alzheimer's patients experience disrupted sleep/wake cycles and circadian rhythms, which may affect brain function, particularly in the hippocampus.
  • Research on Tg-SwDI mice, which have genetic mutations related to human Alzheimer's, shows they exhibit no day/night differences in spatial memory performance, differing from control mice that perform better at night.
  • The Tg-SwDI mice also demonstrate impairments in hippocampal neurophysiology, including altered excitability and synaptic activity, indicating that disruptions in circadian clock gene expression may contribute to cognitive decline.

Article Abstract

Patients with Alzheimer's disease (AD) often have fragmentation of sleep/wake cycles and disrupted 24-h (circadian) activity. Despite this, little work has investigated the potential underlying day/night disruptions in cognition and neuronal physiology in the hippocampus. The molecular clock, an intrinsic transcription-translation feedback loop that regulates circadian behavior, may also regulate hippocampal neurophysiological activity. We hypothesized that disrupted diurnal variation in clock gene expression in the hippocampus corresponds with loss of normal day/night differences in membrane excitability, synaptic physiology, and cognition. We previously reported disrupted circadian locomotor rhythms and neurophysiological output of the suprachiasmatic nucleus (the primary circadian clock) in Tg-SwDI mice with human amyloid-beta precursor protein mutations. Here, we report that Tg-SwDI mice failed to show day/night differences in a spatial working memory task, unlike wild-type controls that exhibited enhanced spatial working memory at night. Moreover, Tg-SwDI mice had lower levels of Per2, one of the core components of the molecular clock, at both mRNA and protein levels when compared to age-matched controls. Interestingly, we discovered neurophysiological impairments in area CA1 of the Tg-SwDI hippocampus. In controls, spontaneous inhibitory post-synaptic currents (sIPSCs) in pyramidal cells showed greater amplitude and lower inter-event interval during the day than the night. However, the normal day/night differences in sIPSCs were absent (amplitude) or reversed (inter-event interval) in pyramidal cells from Tg-SwDI mice. In control mice, current injection into CA1 pyramidal cells produced more firing during the night than during the day, but no day/night difference in excitability was observed in Tg-SwDI mice. The normal day/night difference in excitability in controls was blocked by GABA receptor inhibition. Together, these results demonstrate that the normal diurnal regulation of inhibitory transmission in the hippocampus is diminished in a mouse model of AD, leading to decreased daytime inhibition onto hippocampal CA1 pyramidal cells. Uncovering disrupted day/night differences in circadian gene regulation, hippocampal physiology, and memory in AD mouse models may provide insight into possible chronotherapeutic strategies to ameliorate Alzheimer's disease symptoms or delay pathological onset.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477442PMC
http://dx.doi.org/10.1016/j.nbd.2021.105454DOI Listing

Publication Analysis

Top Keywords

tg-swdi mice
20
day/night differences
16
pyramidal cells
16
normal day/night
12
clock gene
8
gene expression
8
diurnal regulation
8
regulation hippocampal
8
inhibitory transmission
8
precursor protein
8

Similar Publications

Article Synopsis
  • Cerebral amyloid angiopathy (CAA) leads to amyloid-beta deposition in blood vessels, causing neurovascular issues like ischemic strokes that affect brain functions, including breathing and cognition.
  • The study investigates how Transforming Growth Factor Beta (TGF-β) signaling in the retrotrapezoid nucleus (RTN) impacts respiratory and cognitive functions in CAA mice, utilizing techniques like viral injections and behavioral tests.
  • Results indicate that silencing TGF-βR2 in the RTN improves both respiratory and cognitive functions in CAA mice, suggesting that manipulating TGF-β signaling could be a potential therapeutic approach for these impairments.
View Article and Find Full Text PDF

Loss of TREM2 diminishes CAA despite an overall increase of amyloid load in Tg-SwDI mice.

Alzheimers Dement

November 2024

Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota, USA.

Introduction: The microglial receptor triggering receptor expressed on myeloid cells 2 (TREM2) is a major risk factor for Alzheimer's disease (AD). Experimentally, Trem2 deficiency affects parenchymal amyloid beta (Aβ) deposition. However, the role of TREM2 in cerebrovascular amyloidosis, especially cerebral amyloid angiopathy (CAA), remains unexplored.

View Article and Find Full Text PDF

Introduction: Disturbances in microvascular flow dynamics are hypothesized to precede the symptomatic phase of Alzheimer's disease (AD). However, evidence in presymptomatic AD remains elusive, underscoring the need for therapies targeting these early vascular changes.

Methods: We employed a multimodal approach, combining in vivo optical imaging, molecular techniques, and ex vivo MRI, to investigate early capillary dysfunction in Tg-SwDI mice without memory impairment.

View Article and Find Full Text PDF

c-KIT inhibitors reduce pathology and improve behavior in the Tg(SwDI) model of Alzheimer's disease.

Life Sci Alliance

October 2024

Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington DC, USA

Treatments for Alzheimer's disease have primarily focused on removing brain amyloid plaques to improve cognitive outcomes in patients. We developed small compounds, known as BK40143 and BK40197, and we hypothesize that these drugs alleviate microglial-mediated neuroinflammation and induce autophagic clearance of neurotoxic proteins to improve behavior in models of neurodegeneration. Specificity binding assays of BK40143 and BK40197 showed primary binding to c-KIT/Platelet Derived Growth Factor Receptors (PDGFR)α/β, whereas BK40197 also differentially binds to FYVE finger-containing phosphoinositide kinase (PIKFYVE).

View Article and Find Full Text PDF
Article Synopsis
  • Cerebral amyloid angiopathy (CAA) is linked to amyloid-beta deposits in blood vessels, leading to complications like ischemic strokes, metabolic issues, and respiratory dysfunctions, with a focus on the retrotrapezoid nucleus (RTN) for breathing regulation.
  • The study involved CAA model mice and controls to investigate the effects of Transforming Growth Factor Beta (TGF-β) signaling in the RTN, looking at both respiratory and cognitive functions through various tests.
  • Results showed that CAA mice had respiratory and cognitive impairments, but reducing TGF-β signaling in the RTN improved these functions, highlighting the role of TGF-β in contributing to dysfunction in these conditions.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!